$MBX

Guggenheim raised its price target for MBX Biosciences (NASDAQ:MBX) to $150 from $88, citing potential in its obesity drug MBX 4291. The stock has surged 238% over the past year but may be overvalued. Guggenheim's analysis projects $2.6B in risk-adjusted revenue and a 165% upside. MBX reported a Q2 loss of $0.78 per share, with increased R&D expenses. UBS reiterated a Buy rating with a $90 target.

MBX Biosciences (MBX) began its Phase 3 oPTimize trial for canvuparatide, a treatment for chronic hypoparathyroidism. The global study will enroll 160 adults, with primary endpoints assessing serum calcium normalization and vitamin D independence. Canvuparatide is a long-acting parathyroid hormone peptide prodrug. MBX's stock closed at $66.76 and is up 1.86% in pre-market trading.

MBX Biosciences dosed the first patient in its Phase 3 oPTimize trial for once-weekly canvuparatide, a treatment for chronic hypoparathyroidism. The global trial will enroll 160 adults and evaluate efficacy and safety over 26 weeks. Positive Phase 2 results support canvuparatide's potential as a PTH replacement therapy. MBX Biosciences (Nasdaq: MBX) is a clinical-stage biopharmaceutical company focused on endocrine and metabolic disorders.

Moonberg (presale token $MBX) said Stage 1 sold out after raising over $200,000 in 18 hours, with product features including Morpheus and other tools live, according to the company. Separately, the article cites Bitcoin ($BTC) trading in a $62,000 to $66,000 range and highlights regulatory delays to the CLARITY Act that could keep volatility elevated.

MBX Biosciences, Inc. (MBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting

MBX Biosciences, a Carmel-based biopharmaceutical company, said CEO and co-founder Kent Hawryluk stepped down. Steve Hoerter, previously executive chairman, became CEO and board chair, and John Smither was appointed CFO. The changes took effect Monday. MBX, which raised over $213M and went public in Sept 2024, is advancing precision peptide therapies including canvuparatide (Phase 3).

Midday movers included CleanSpark, up 11% after a 20-year Georgia data center lease totaling $6.6B in contracted revenue. HCA Healthcare fell over 7% after lowering full-year EPS to $28.70-$30.50. Banks and others moved on Q2 results, including Goldman Sachs up 7% and IBM down 25% on weaker preliminary earnings.

MBX Biosciences (Nasdaq: MBX) announced leadership changes. Steve Hoerter, previously Executive Chairman, becomes Chairman and CEO, replacing Kent Hawryluk, who steps down as President and CEO. John Smither, interim CFO since March 2026, is appointed CFO. The company said it remains on track for Phase 3 canvuparatide and obesity pipeline milestones in 2H 2026.

MBX Biosciences, Inc. (MBX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001776111 0001776111 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2

MBX Biosciences (NASDAQ:MBX) shares fell 8.3% in after-hours after the company announced leadership changes. Steve Hoerter became Chairman and CEO, replacing Kent Hawryluk. John Smither was appointed permanent CFO. MBX said it remains on track for Phase 3 canvuparatide milestones and other 2026 pipeline updates.